Business Wire

MODERN-HEALTH

16.7.2024 08:01:25 CEST | Business Wire | Pressemeddelelse

Del
Generali Health Solutions vælger Modern Health som eksklusiv mental sundhedspartner

Modern Health, en førende mental sundhedsplatform på det globale arbejdsmarked og Generali Health Solutions GmbH offentliggør i dag et eksklusivt partnerskab. Som udbyder af bevist effektive sundhedsprogrammer er Generali Health Solutions GmbH en del af den internationale Generali Group, som er en af de største globale udbydere af forsikringer og formueforvaltning. Dette partnerskab kommer på et tidspunkt, hvor der er et stigende behov for support af den mentale sundhed på arbejdspladsen. Depression er den førende årsag til uarbejdsdygtighed i verden med 12 milliarder mistede arbejdsdage pga. depression og angst, hvilket giver et anslået årligt tab i produktivitet på USD 1 billion. Partnerskabet gør det nu muligt for arbejdsgivere i mere end 50 lande at investere i mental sundhed for deres medarbejdere, hvilket er et stort skridt fremad i prioriteringen af mental sundhed på global skala.

“Vi er overbeviste om, at global retfærdighed i mental sundhed skal gå længere end adgang til eller appoversættelser – det skal være en integreret del af hvert enkelt aspekt i omsorg for og afspejling af hver person og deres unikke oplevelser,” siger Alyson Watson, grundlægger og adm. direktør for Modern Health. “Vi sætter enkeltpersoner i centrum for deres mentale sundhedsforløb og sikrer, at mental sundhed føles så personlig som den person, den skal hjælpe. Vi er imponerede over Generalis tilsagn til deres kunder og er beærede over at blive partner for at forbedre livet for mennesker over hele verden med ægte global og personlig mental sundhedsomsorg, der giver de bedste resultater for medlemmer, hvad der behov må være, eller hvor de bor.”

Dette samarbejde giver arbejdsgivere mulighed for nemt at få adgang til Modern Healths omfattende globale mentale sundhedsfordele på det globale arbejdsmarked via Generali Health Solutions. Dette omfatter en-til-en-support fra autoriserede terapeuter og certificerede coaches, gruppefællesskabs Circles, de første i branchen Pathways, krisesupport og en omfattende samling digitale ressourcer via selvbetjening til emotionelle, professionelle, sociale, økonomiske og fysiske velfærdsbehov – alt sammen på en platform. Modern Healths innovative og bæredygtige trindopdelte omsorgsmetode giver en solid, beviselig support for hele den globale arbejdsstyrke, der medfører målbare resultater for alle, lige meget hvad de lever med.

"Vores mål er et give vores kunder innovative løsninger, som fremmer sundhed og modstandsdygtighed på arbejdspladsen og således øge medarbejdernes produktivitet," forklarer Dr. Markus Homann, adm. direktør for Generali Health Solutions. “Vi ved, at der er et stigende behov for velfærdssupport på arbejdspladsen og ved at slå os sammen med Modern Health kan vi nemt og uden problemer forbinde vores kunder til det bedste på markedet for globale mental sundhedspleje.”

Gå til Modern Health eller Generali Health Solutions for at få mere at vide.

Om Modern Health

Modern Health er en omfattende global løsning på mental sundhed, som tilbyder medarbejdere adgang til en-til-en-, gruppe- og selvbetjenings digitale ressourcer til deres emotionelle, professionelle, sociale, økonomiske og fysiske velfærdsbehov - alt på én platform. Når en person ønsker proaktivt at håndtere stress eller behandle depression, guider Modern Health disse mennesker til den rigtige hjælp på det rigtige tidspunkt.

Modern Health støttes af investorer som Kleiner Perkins, Founders Fund, John Doerr, Y Combinator og Battery Ventures og skaffede mere end USD 170 millioner på mindre end to år, hvilket gør Modern Health til det hurtigst helt kvindegrundlagte firma i USA til at nå Unicorn-status.

Om Generali Health Solutions

Generali Health Solutions GmbH (GHS) er en del af den internationale Generali Group. Som udbyder af beviseligt effektive sundhedsprogrammer, som kan bruges i virksomheder, forsikringsselskaber og andre institutioner, skaber GHS primært løsninger, som hjælper medarbejdere med at fortsætte med at være produktive og mere tilfredse. Derudover er målet at reducere produktivitetstab og behandlingsomkostninger pga. Sygdom.

For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.

Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20240716732760/da/

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye